
Sign up to save your podcasts
Or
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
3,896 Listeners
4,275 Listeners
8,630 Listeners
32,260 Listeners
1,520 Listeners
656 Listeners
111,746 Listeners
2,304 Listeners
6,751 Listeners
2,022 Listeners
5,438 Listeners
15,220 Listeners
4,367 Listeners
8,695 Listeners
10,508 Listeners
1,457 Listeners
446 Listeners